Skip to main content

Table 3 Application, response and survival of systemic therapy

From: Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients

  Patients Response Overall survival
Lines of systemic therapy n % PR* SD* NE* PD* Median OS 95% CI
1 352 100 30.7 29.0 20.7 19.6 7.6 6.8-8.5
2 183 52.0 14.8 31.7 19.7 33.8 6.2 5.0-7.4
3 97 27.6 12.4 23.7 22.7 41.2 5.2 3.5-7.0
4 48 13.6 14.6 20.8 31.3 33.4 5.1 3.7-6.5
5 20 5.7 5.0 30.0 10 55.0 4.5 1.9-7.1
6 8 2.3 37.5 12.5 12.5 37.5 11.1 3.1-19.1
7 2 0.6 0 0 50 50   
  1. Survival is stated in months from the beginning of the respective line of systemic therapy. Response was assessed according to RECIST: PR, Partial response; SD, stable disease; NE, not evaluable; PD, progressive disease. CI, confidence interval. OS, overall survival. * Because of rounding, not all percentages sum to 100.